

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-71. (Cancelled)

72. (New) A compound comprising a chemically modified or unmodified double-stranded nucleic acid compound that is 19-23 nucleobases in length,

wherein a first strand has at least 19 contiguous nucleobases of a polynucleotide selected from the group consisting of SEQ ID NOs: 17, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 59, 61, 65, 67, 69, 73, and 81,

and wherein a second strand is 100% complementary to the first strand.

73. (New) The compound of **Claim 72** which is blunt-ended or canonical.

74. (New) The compound of **Claim 72** comprising at least one chemical modification to a sugar, nucleobase, or internucleoside linkage.

75. (New) The compound of **Claim 74** wherein each chemical modification to the sugar is a 2' modification.

76. (New) The compound of **Claim 75** wherein each 2' sugar modification is independently selected from the group consisting of 2'-O-methoxyethyl (2'-MOE), 2'-O-methyl, locked nucleic acid (LNA) and 2'-fluoro.

77. (New) The compound of **Claim 76** wherein each 2' modification is a 2'-O-methoxyethyl (2'-MOE).

78. (New) The compound of **Claim 76** wherein each 2' modification is a 2'-O-methyl.

79. (New) The compound of **Claim 76** wherein each 2' modification is a 2'-fluoro.

80. (New) The compound of **Claim 76** wherein each 2' modification of the sugar results in a bicyclic sugar.

81. (New) The compound of **Claim 80** wherein the bicyclic modification is a locked nucleic acid (LNA).

82. (New) The compound of **Claim 74** wherein the chemical modification to the sugar is a 4' thio.

83. (New) The compound of **Claim 75** comprising two or more chemically distinct 2' sugar modifications.

84. (New) The compound of **Claim 74** comprising at least one internucleoside linkage modification.

85. (New) The compound of **Claim 84** comprising mixed phosphorothioate and phosphodiester linkages.

86. (New) The compound of **Claim 85** comprising alternating phosphorothioate and phosphodiester internucleoside linkages.

87. (New) The compound of **Claim 76** comprising at least one internucleoside linkage modification.

88. (New) The compound of **Claim 87** comprising mixed phosphorothioate and phosphodiester linkages.

89. (New) The compound of **Claim 88** comprising alternating phosphorothioate and phosphodiester internucleoside linkages.

90. (New) The compound of **Claim 72** comprising a conjugate.

91. (New) The compound of **Claim 72** wherein the first strand consists of SEQ ID NO 81.

92. (New) The compound of **Claim 91** wherein the compound is canonical.

93. (New) A pharmaceutical composition comprising the compound of **Claim 72** and a pharmaceutically acceptable carrier or diluent.

94. (New) A method for treating a condition associated with survivin expression or overexpression comprising administering to an animal, particularly a human, an effective amount of a compound of **Claim 72**.

95. (New) The method of **Claim 94** wherein the condition is cancer.

96. (New) The method of **Claim 95** wherein the cancer is selected from the group consisting of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, lung cancer, bladder cancer, ovarian cancer, renal cancer, glioblastoma, pancreatic cancer and non-Hodgkin's lymphoma.